Skip to main
STRO

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 0%
Sell 14%
Strong Sell 0%

Bulls say

Sutro Biopharma Inc. is leveraging its proprietary XpressCF platform to develop next-generation antibody-drug conjugates (ADCs), notably STRO-004, which exhibits promising preclinical safety data and improved clinical benefits. The company has demonstrated strong execution across its ADC pipeline, suggesting that its engineering approach will result in higher drug exposures and better tolerability compared to current market offerings. The anticipated synergies between STRO-004 and existing therapies could position the product to capture significant market share, thereby enhancing Sutro's overall financial outlook.

Bears say

Sutro Biopharma faces significant challenges in the adoption of its antibody-drug conjugates (ADCs) due to persistent ocular toxicity issues, which hinder oncologists' willingness to engage patients in treatment. The industry expert underscores that approximately 15-20% of patients experience treatment interruptions related to these adverse reactions, leading to delays in care as patients struggle to access specialized ophthalmologic support. Additionally, the complexities surrounding pseudokinases in cancer biology add uncertainty to the efficacy and market potential of Sutro's pipeline, increasing concerns regarding the company's ability to achieve its valuation targets.

STRO has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Buy based on their latest research and market trends.

According to 7 analysts, STRO has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.